⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Supplementary Figure S7 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Ilango Balakrishnan Krishna Madhavan Angela Pierce Joshua Michlin Breauna Brunt Senthilnath Lakshmanachetty Dong Wang John DeSisto Zachary James Nuss Nathan Davidson Faye Walker Ammu Suresh Andrew M. Donson Bridget Sanford Kenneth L. Jones Etienne Danis Siddhartha S. Mitra Adam L. Green Nathan Dahl Rajeev Vibhakar Sujatha Venkataraman

View Full Paper

Ask AI

Bookmark

Share

Key Points

Intrathecal treatment significantly reduces tumor burden in diffuse midline glioma, providing a promising new approach.
BLI intensities showed a notable decrease in tumor size alongside increasing animal body weight after treatment.
Observational analysis found that MRI confirmed clearance of pons tumors, with no apparent toxicity from the treatment protocol.
The implications of this treatment highlight its potential as a non-toxic therapeutic option for diffuse midline glioma patients.

Implication

Intrathecal anti-CD99 antibody treatment reduces tumor burden in diffuse midline glioma, suggesting potential efficacy without toxicity.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Balakrishnan et al. (2025) studied this question.

synapsesocial.com/papers/68af56faad7bf08b1eadd1af https://doi.org/10.1158/0008-5472.29918852

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S8 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
2Supplementary Figure S10 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
3Supplementary Figure S9 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
4Supplementary Figure S6 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
5Supplementary Figure S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025

More related papers

Supplementary Figure S3 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
Supplementary Figure S2 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025
Supplementary FIgure S4 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma2025